CIS
VIR icon

Capital International Sarl’s Vir Biotechnology VIR Stock Holding History

Capital International Sarl’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,022
Closed -$281K – 219
2022
Q2 		$281K Sell
11,022
-17,470
-61% -$408K 0.02% 206
2022
Q1 		$733K Buy
28,492
+5,153
+22% +$153K 0.04% 236
2021
Q4 		$977K Buy
+23,339
New +$914K 0.05% 226
2021
Q3 		– Sell
-4,900
Closed -$232K – 253
2021
Q2 		$232K Buy
4,900
+240
+5% +$10.9K 0.02% 240
2021
Q1 		$239K Sell
4,660
-2,995
-39% -$161K 0.02% 235
2020
Q4 		$205K Buy
7,655
+358
+5% +$11.6K 0.02% 227
2020
Q3 		$251K Buy
+7,297
New +$314K 0.03% 207

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Sarl's VIR Position: Q3 2022 in Review

Capital International Sarl sold out of Vir Biotechnology (VIR) in Q3 2022, closing a stake of 11,022 shares — an estimated $281K sold.

Capital International Sarl first reported a position in VIR in Q3 2020 and held it in 7 quarters. The position peaked at $977K in Q4 2021. 221 funds tracked by Wall St. Rank hold VIR as of Q3 2022.

  • Capital International Sarl reported no remaining Vir Biotechnology position as of Q3 2022 after selling out during the quarter.
  • Capital International Sarl sold 11,022 Vir Biotechnology shares in Q3 2022, an estimated $281K.
  • Capital International Sarl first reported a position in Vir Biotechnology in Q3 2020 and held it in 7 quarters.
  • Capital International Sarl's Vir Biotechnology position peaked at $977K in Q4 2021.
  • 221 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2022.

Based on Capital International Sarl's 13F filing for Q3 2022, filed 14 Nov 2022.